Phaseline

Companies › Noema Pharma

Noema Pharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Psychiatry, Neurology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Basimglurant (NOE-101)
Metabotropic glutamate receptor 5 modulator
GRM5Phase 2Trigeminal NeuralgiaFeb 2027
Gemlapodect (NOE-105)
selective PDE10A inhibitor
PDE10APhase 2Tourette Syndrome–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06315751Gemlapodect (NOE-105)Phase 2Tourette SyndromePsychiatryJun 2026
NCT05217628Basimglurant (NOE-101)Phase 2Trigeminal NeuralgiaNeurologyFeb 2027

Targets

PDE10A (1) GRM5 (1)

Companies with the same targets

–

Companies built like this

Reunion Neuroscience TrueBinding Spinogenix Shanghai Auzone Biological Technology MapLight Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.